MedTrace Logo

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

NCT00373659 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-06-13

No results posted yet for this study

Summary

This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab (Lucentis)

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Philip J Rosenfeld, MD PhD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373659 on ClinicalTrials.gov